Klin Farmakol Farm. 2024;38(2):60-66 | DOI: 10.36290/far.2024.009

Modern pharmacotherapy of Parkinson's disease

Kateřina Menšíková
Neurologická klinika LF UP a FN Olomouc

Despite intensive research, the current treatment of Parkinson's disease is still symptomatic treatment and its management is primarily aimed at controlling motor symptoms. Dopaminergic agents that replace the action of the missing dopamine remain the mainstay of current therapy. In recent decades, significant progress has been made in the treatment of advanced stage of disease using interventional methods such as treatment with pump systems and deep brain stimulation. An important part of the treatment is the influence of non-motor symptoms, which significantly affect the quality of life of patients. New treatment strategies capable to affect the development and progression of the disease, which are still in the preclinical and clinical research phase, include various treatment procedures with the aim to influence the formation and aggregation of pathological forms of alpha-synuclein and modify the spread of the pathological process in the brain.

Keywords: Parkinson's disease, dopaminergic treatment, non-motor symptoms, new treatment strategies.

Accepted: June 28, 2024; Published: July 15, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Menšíková K. Modern pharmacotherapy of Parkinson's disease. Klin Farmakol Farm. 2024;38(2):60-66. doi: 10.36290/far.2024.009.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Balestrino R, et al. Parkinson disease. Eur J Neurol 2020; 27(1):27-42. Go to original source... Go to PubMed...
    2. Spillantini MG, et al. α-Synuclein in Lewy Bodies. Nature 1997;388:839-840. Go to original source... Go to PubMed...
    3. Calabresi P, et al. Alpha-synuclein in Parkinson´s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 2023;14:176. Go to original source... Go to PubMed...
    4. Pardo-Moreno T, et al. Current Treatments and New Tentative Therapies for Parkinson's Disease. Pharmaceutics 2023; 15(3):770. Go to original source... Go to PubMed...
    5. Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 2002; 23:65-70. Go to original source... Go to PubMed...
    6. Obeso JA, et al. The origin of motor fluctuation in Parkinson´s disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004;62:17-30. Go to original source... Go to PubMed...
    7. Kaňovský P, et al. Farmakoterpie pokročilé Parkinsonovy nemoci ve světle doporučených postupů. Neurol Praxi 2010;11(4):244-249.
    8. Seppi K, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review: Treatment of the Nonmotor Symptoms in PD. Mov Disord 2019;34(2):180-198. Go to original source... Go to PubMed...
    9. Prokeš M, et al. Antiparkinsonika, psychické poruchy u pacientů s Parkinsonovou nemocí a lékové interakce. Klin Farmakol Farm 2018;32(2):13-19. Go to original source...
    10. Slíva J. Lékové interakce antiepileptik a antiparkinsonik. Neurol Praxi 2010;11(2).
    11. Aboukarr A, et al. Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors. Can J Hosp Pharm. 2018;71(3):196-207. Go to original source...
    12. Freijzer PL, Brenminkmeijer JH. Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation. Ned Tijdschr Geneeskd 2002;146(12):574-575.
    13. Norman C, Hesslinger B, Frauenknecht S, et al. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 1997; 30:263-265. Go to original source... Go to PubMed...
    14. Edwards M. Adverse interaction of levodopa with tricyclic antidepressants. Practitioner 1982;226:1447-1449.
    15. Marsh L. Depression in Parkinson´s disease: current knowledge. Curr Neurol Neurosci Rep 2013;13(12):409. doi: 10.1007/s11910-013-0409-5. Go to original source... Go to PubMed...
    16. Lees AJ, et al. Tiapride in levodopa-induced involuntary movements J Neurol Neurosurg Psychiatry 1979;42:380-383. Go to original source... Go to PubMed...
    17. Dafsari HS, et al. Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. Mov Disord 2019;34:353-365. Go to original source... Go to PubMed...
    18. Kanovsky P, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two- -year, prospective follow-up. Mov Disord 2002;17:188-1891. Go to original source... Go to PubMed...
    19. Katzenschlager R, et al. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2018; 17(9):749-759. Go to original source... Go to PubMed...
    20. Katzenschlager R, et al. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord 2021;83:79-85. Go to original source... Go to PubMed...
    21. Henriksen T, et al. Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience. J Neural Transm 2023;130: 1475-1484. Go to original source... Go to PubMed...
    22. Menšíková K, et al. Současný stav farmakoterapie extrapyramidových onemocnění. Neurol Praxi 2021;22(3):183-193. Go to original source...
    23. Menšíková K, et al. The long-term effect of continuous subcutaneous apomorphine infusions on camptocormia in Parkinson's disease. Parkinsonism Relat Disord 2020;75:14-16. Go to original source... Go to PubMed...
    24. Poltawski L, et al. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. Mov Disord 2009;24:115-118. Go to original source... Go to PubMed...
    25. Antonini A, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism Relat Disord 2017;45:13-20. Go to original source... Go to PubMed...
    26. Poewe W, et al. Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. Neurodegener Dis Manag 2019;9:39-46. Go to original source... Go to PubMed...
    27. Wirdefeldt K, et al. Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review. CNS Drugs 2016;30:381-404. Go to original source... Go to PubMed...
    28. Blaise AS, et al. Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study. Rev Neurol (Paris) 2020;176:268-276. Go to original source... Go to PubMed...
    29. Amande K, et al. Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel. Brain Behav 2021;11:e2408. Go to original source... Go to PubMed...
    30. Rosebraugh M, et al. Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021;90(1):52-61. Go to original source... Go to PubMed...
    31. Rosebraugh M, et al. Foslevodopa/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons Dis 2021;11(4):16951702.b. Go to original source... Go to PubMed...
    32. Rosebraugh M, et al. Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa -arbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat Disord 2022;97:68-72. Go to original source... Go to PubMed...
    33. Baláž M, et al. Subkutánní forma levodopy - nová intervenční terapie Parkinsonovy nemoci. Neurol. Praxi 2023; 24(3):223-226. Go to original source...
    34. Krack P, et al. Deep Brain Stimulation in Movement Disorders: From Experimental Surgery to Evidence-Based Therapy. Mov Disord 2019;34:1795-1810. Go to original source... Go to PubMed...
    35. Baláž M. Hluboká mozková stimulace u Parkinsonovy nemoci. Neurol Praxi 2013;14:229-231.
    36. Schüpbach WM, et al. EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:610-622. Go to original source... Go to PubMed...
    37. Krahulík D, et al. O-Arm Navigated Frameless and Fiducial-Less Deep Brain Stimulation. Brain Sci 2020;10:683. Go to original source... Go to PubMed...
    38. Habets JGV, Heijmans M, Kuijf ML, et al. An update on adaptive deep brain stimulation in Parkinson's disease. Mov Disord 2018;33:1834-184. Go to original source... Go to PubMed...
    39. McFarthing K, et al. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline. J Parkinsons Dis 2020;10:757-774. Go to original source... Go to PubMed...
    40. Hung AY, et al. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned. Neurotherapeutics 2020;17:1393-1405. Go to original source... Go to PubMed...
    41. Vijiaratnam N, et al. Progress towards therapies for disease modification in Parkinson´s disease. Lancet Neurol 2021; 20(7):559-571. Go to original source... Go to PubMed...
    42. Šonka K. Porucha chování v REM spánku. Neurol. pro praxi. 2008;9(5):297-299.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.